1. Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications
   David S. Schrump, 2009, Clinical Cancer Research CrossRef
2. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function
   Jennifer L. Brogdon et al, 2007, Blood CrossRef
3. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells
   Clint Mitchell et al, 2007, Molecular Cancer Therapeutics CrossRef
4. Deacetylase inhibitors - focus on non-histone targets and effects
   Matthias Ocker, 2010, World Journal of Biological Chemistry CrossRef
5. Ornithine decarboxylase activity in tumor cell lines correlates with sensitivity to cell death induced by histone deacetylase inhibitors
   Laura R. Saunders et al, 2006, Molecular Cancer Therapeutics CrossRef
6. Histone Deacetylase Inhibitors: Overview and Perspectives
   Milos Dokmanovic et al, 2007, Molecular Cancer Research CrossRef